By continuing to use the site you agree to our Privacy & Cookies policy

New contraceptive pill linked to lighter and shorter periods

A combined oral contraceptive containing a new hormone combination has been launched in the UK.

The pill branded as Zoely is a combination of nomegestrol acetate 2.5mg and 17ß-estradiol 1.5mg (NOMAC/E2).  

NOMAC/E2 contains a monophasic combination of two hormones: nomegestrol acetate, a highly selective progesterone-derived progestogen that has a 46-hour half-life, and 17ß-estradiol, an oestrogen that is structurally identical to endogenous human 17ß-estradiol.

The combination of contraceptive hormones is delivered through a 24-day active tablet and four-day placebo tablet dosing regimen.

According to trial data, it is associated with withdrawal bleeds of shorter duration and lighter intensity than a combination containing 3mg drospirenone and 30μg ethinylestradiol (DRSP/EE).

However, trials also revealed that 51.2% of women receiving NOMAC/E2 experienced adverse events compared to 37% of women randomised to DRSP/EE.

The most frequently reported NOMAC/E2 adverse events were acne, irregular withdrawal bleeding, increased weight and headache.

The product is manufactured by the pharmaceutical giant MSD.

Readers' comments (2)

  • Best to avoid the pill altogether.

    Unsuitable or offensive?

  • it can take a very long time before the full impact of the side effects are discovered, when is often too late.

    Unsuitable or offensive?

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!